Nature Communications (Jan 2022)
Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database
- Lee S. Nguyen,
- Leslie T. Cooper,
- Mathieu Kerneis,
- Christian Funck-Brentano,
- Johanne Silvain,
- Nicolas Brechot,
- Guillaume Hekimian,
- Enrico Ammirati,
- Badr Ben M’Barek,
- Alban Redheuil,
- Estelle Gandjbakhch,
- Kevin Bihan,
- Bénédicte Lebrun-Vignes,
- Stephane Ederhy,
- Charles Dolladille,
- Javid J. Moslehi,
- Joe-Elie Salem
Affiliations
- Lee S. Nguyen
- CMC Ambroise Paré, Research & Innovation (RICAP)
- Leslie T. Cooper
- Department of Cardiovascular Medicine, Mayo Clinic
- Mathieu Kerneis
- Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), INSERM UMRS 1166
- Christian Funck-Brentano
- Department of Pharmacology, Sorbonne University, INSERM CIC Paris-Est, AP-HP, ICAN, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital
- Johanne Silvain
- Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), INSERM UMRS 1166
- Nicolas Brechot
- Department of Critical Care Medicine, AP-HP, Sorbonne Université, Pitié-Salpêtrière
- Guillaume Hekimian
- Department of Critical Care Medicine, AP-HP, Sorbonne Université, Pitié-Salpêtrière
- Enrico Ammirati
- “De Gasperis” Cardio Center and Transplant Center, Niguarda Hospital
- Badr Ben M’Barek
- CMC Ambroise Paré, Research & Innovation (RICAP)
- Alban Redheuil
- Department of Cardiovascular Imagery, AP-HP, Sorbonne Université, Pitié-Salpêtrière
- Estelle Gandjbakhch
- Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), INSERM UMRS 1166
- Kevin Bihan
- Department of Pharmacology, Sorbonne University, INSERM CIC Paris-Est, AP-HP, ICAN, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital
- Bénédicte Lebrun-Vignes
- Department of Pharmacology, Sorbonne University, INSERM CIC Paris-Est, AP-HP, ICAN, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital
- Stephane Ederhy
- Department of Cardiology, AP-HP, Sorbonne Université, Pitié-Salpêtrière
- Charles Dolladille
- Department of Pharmacology, CHU de Caen
- Javid J. Moslehi
- Departments of Medicine and Pharmacology, Cardio-oncology Program, Vanderbilt University Medical Center
- Joe-Elie Salem
- Department of Pharmacology, Sorbonne University, INSERM CIC Paris-Est, AP-HP, ICAN, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital
- DOI
- https://doi.org/10.1038/s41467-021-27631-8
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 10
Abstract
Multiple drugs have been in the past associated with myocarditis. Here the authors perform a pharmacovigilance study and analyze 5108 reports of drug-induced myocarditis reporting temporal trends and overall mortality and identifying emerging drug classes among the treatments associated with myocarditis.
